Louis-Armstrong

FDA OKs ‘Game Changer’ Radiotracer for Prostate Cancer

WASHINGTON — The FDA approved the first PET imaging agent that targets prostate-specific membrane antigen (PSMA)…

FDA OK’s Rare Metabolic Disorder Tx; Junk on the Big Screen

Lumasiran (Oxlumo), the first treatment ever for the rare metabolic disorder primary hyperoxaluria type 1, gained…